Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life.

Trial Profile

Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2014

At a glance

  • Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; MMR-varicella zoster virus vaccine
  • Indications Chickenpox; Measles; Mumps; Rubella
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 18 Feb 2011 Actual end date (Nov 2005) added as reported by ClinicalTrials.gov.
    • 02 Aug 2006 Status changed from recruiting to completed.
    • 05 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top